Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
LUX-Lung 7: is there enough data for a final conclusion?
Orlandi A, Calegari MA, Barone C. Orlandi A, et al. Among authors: calegari ma. Lancet Oncol. 2016 Jul;17(7):e267-e268. doi: 10.1016/S1470-2045(16)30216-9. Lancet Oncol. 2016. PMID: 27396644 No abstract available.
KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients.
Basso M, Strippoli A, Orlandi A, Martini M, Calegari MA, Schinzari G, Di Salvatore M, Cenci T, Cassano A, Larocca LM, Barone C. Basso M, et al. Among authors: calegari ma. Br J Cancer. 2013 Jan 15;108(1):115-20. doi: 10.1038/bjc.2012.526. Epub 2012 Nov 22. Br J Cancer. 2013. PMID: 23175150 Free PMC article.
New life for retrospective study in the precision oncology era.
Orlandi A, Basso M, Calegari MA, Barone C. Orlandi A, et al. Among authors: calegari ma. Ann Oncol. 2015 Nov;26(11):2352-3. doi: 10.1093/annonc/mdv371. Epub 2015 Sep 7. Ann Oncol. 2015. PMID: 26347104 Free article. No abstract available.
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Orlandi A, Calegari MA, Martini M, Cocomazzi A, Bagalà C, Indellicati G, Zurlo V, Basso M, Cassano A, Larocca LM, Barone C. Orlandi A, et al. Among authors: calegari ma. Clin Transl Oncol. 2016 Oct;18(10):988-95. doi: 10.1007/s12094-015-1471-z. Epub 2016 Jan 7. Clin Transl Oncol. 2016. PMID: 26742940
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC.
Pinto C, Normanno N, Orlandi A, Fenizia F, Damato A, Maiello E, Tamburini E, Di Costanzo F, Tonini G, Bilancia D, Corsi D, Pisconti S, Ferrau F, Gori S, Daniele B, Zaniboni A, Soto Parra H, Frassinetti GL, Iaffaioli RV, Cassata A, Zampino MG, Repetto L, Calegari MA, Barone C; all the investigators of ERMES study group.. Pinto C, et al. Among authors: calegari ma. Future Oncol. 2018 Jun;14(14):1339-1346. doi: 10.2217/fon-2017-0592. Epub 2018 May 30. Future Oncol. 2018. PMID: 29846100 Clinical Trial.
35 results